Literature DB >> 18564602

Towards quality, comprehensiveness and excellence. The accreditation project of the Organisation of European Cancer Institutes (OECI).

Mahasti Saghatchian1, Henk Hummel, Renée Otter, Dominique de Valeriola, Wim Van Harten, Angelo Paradiso, Bert Koot, Ulrik Ringborg, Thomas Tursz.   

Abstract

There are important gaps in the health status of citizens across Europe, as measured by life expectancy, mortality or morbidity data (Report for the European Commission on the health status of the European Union, 2003). Among the main determinants of the major causes of mortality and morbidity, stated in this report, stands recurrently access to quality healthcare. There is a fundamental need to define quality indicators and set minimal levels of performance quality criteria for healthcare. There is a need to integrate research into healthcare and to provide patients with equity of access to such high quality care. Oncology is a specialty particularly suited to experimenting a first application of accreditation at European level. The Organisation of European Cancer Institutes is a growing network of cancer Centres in Europe. The focus of the OECI is to work with professionals and organisations with regard to prevention, care, research, development, patient's role and education. In order to fulfil its mission, the OECI initiated in 2002 an accreditation project with three objectives: * to develop a comprehensive accreditation system for oncology care, taking into account prevention, care, research, education and networking. * to set an updated database of cancer centres in Europe, with exhaustive information on their resources and activities (in care, research, education and management) * to develop a global labelling tool dedicated to comprehensive cancer centres in Europe, designating the various types of cancer structures, and the comprehensive cancer centres of reference and Excellence. An accreditation tool has been established, defining standards and criteria for prevention, care, research, education and follow-up activities. A quantitative database of cancer centres is integrated in the tool, with a questionnaire, that provides an overall view of the oncological landscape in OECI cancer centres in Europe. Data on infrastructures, resources and activities have been collected. This OECI accreditation tool will be launched in autumn 2008 for all cancer centres in Europe. It serves as a basis for the development of the labelling tool for cancer structures in Europe, with a focus on Comprehensiveness and Excellence labels. Quality assessment and improvement is a critical need in Europe and is addressed by the OECI for cancer care in Europe. Accreditation is a well accepted process and is feasible. Standards and criteria as well as an accreditation tool have been developed. The OECI questionnaire gives an accurate vision of cancer institutions throughout Europe, helping assessing the needs and providing standards. The accreditation project is a long-term complete and voluntary process with external and internal added value, an active process of sharing information and experience that should help the whole cancer community reach comprehensiveness and excellence.

Entities:  

Mesh:

Year:  2008        PMID: 18564602     DOI: 10.1177/030089160809400206

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  7 in total

1.  The role of funding and policies on innovation in cancer drug development.

Authors:  P Kanavos; R Sullivan; G Lewison; W Schurer; S Eckhouse; Z Vlachopioti
Journal:  Ecancermedicalscience       Date:  2010-02-03

Review 2.  Has the US Cancer Centre model been 'successful'? Lessons for the European cancer community.

Authors:  Richard Sullivan
Journal:  Mol Oncol       Date:  2009-04-01       Impact factor: 6.603

Review 3.  Towards a mission-oriented approach to cancer in Europe: an unmet need in cancer research policy.

Authors:  Julio E Celis; Manuel Heitor
Journal:  Mol Oncol       Date:  2019-02-01       Impact factor: 6.603

Review 4.  Quality-assured research environments for translational cancer research.

Authors:  Anton Berns
Journal:  Mol Oncol       Date:  2019-02-22       Impact factor: 6.603

5.  Towards a Cancer Mission in Horizon Europe.

Authors:  Anton Berns; Ulrik Ringborg; Alexander Eggermont; Michael Baumann; Fabien Calvo; Angelika Eggert; Carolina Espina; Douglas Hanahan; Denis Lacombe; Francesco de Lorenzo; Simon Oberst; Thierry Philip; Joachim Schüz; Josep Tabernero; Julio E Celis
Journal:  Mol Oncol       Date:  2019-11       Impact factor: 6.603

6.  Towards a cancer mission in Horizon Europe: recommendations.

Authors:  Anton Berns; Ulrik Ringborg; Julio E Celis; Manuel Heitor; Neil K Aaronson; Nancy Abou-Zeid; Hans-Olov Adami; Kathi Apostolidis; Michael Baumann; Alberto Bardelli; René Bernards; Yvonne Brandberg; Carlos Caldas; Fabien Calvo; Caroline Dive; Angelika Eggert; Alexander Eggermont; Carolina Espina; Frederik Falkenburg; Jérôme Foucaud; Douglas Hanahan; Ulrike Helbig; Bengt Jönsson; Mette Kalager; Sakari Karjalainen; Miklós Kásler; Pamela Kearns; Klas Kärre; Denis Lacombe; Francesco de Lorenzo; Françoise Meunier; Gerd Nettekoven; Simon Oberst; Péter Nagy; Thierry Philip; Richard Price; Joachim Schüz; Eric Solary; Peter Strang; Josep Tabernero; Emile Voest
Journal:  Mol Oncol       Date:  2020-08       Impact factor: 6.603

7.  Shifting cancer care towards Multidisciplinarity: the cancer center certification program of the German cancer society.

Authors:  Christoph Kowalski; Ullrich Graeven; Christof von Kalle; Hauke Lang; Matthias W Beckmann; Jens-Uwe Blohmer; Martin Burchardt; Michael Ehrenfeld; Jan Fichtner; Stephan Grabbe; Hans Hoffmann; Heinrich Iro; Stefan Post; Anton Scharl; Uwe Schlegel; Thomas Seufferlein; Walter Stummer; Dieter Ukena; Julia Ferencz; Simone Wesselmann
Journal:  BMC Cancer       Date:  2017-12-14       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.